



Office of Retations L 22 Docket No. MCP 264

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Codispoti

Serial No.

09/709,069

Art Unit: 1614

Filed

9 November 2000

Examiner: Jagoe

Confirmation number: 3552

For

METHOD FOR TREATING MIGRAINE SYMPTOMS WITH IBUPROFEN

AND SALTS THEREOF

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

April 2003

(Date)

Michele Galka Mangini, Esq.

Name of applicant, assignee, or Registered Representative

RECEIVED

MAY 0 6 2003

OFFICE OF PETITIONS

Assistant Commissioner for Patents

Washington, D.C. 20231

PETITION UNDER 37 C.F.R. §1.313(b) WITHDRAWAL FROM ISSUE - ISSUE FEE PAID

Dear Sir:

Box DAC

05/05/2003 CNGUYEN 00000135 100750

01 FC:1460

130.00 CH

Applicant petitions that the above identified application be withdrawn from issue. The issue fee was paid on 14 April 2003.

Applicant seeks withdrawal from issue of this application for consideration of Applicant's request for continued examination under 37 CFR §1.114 ("RCE") and information disclosure statement under 37 CFR §1.97 ("IDS"). The RCE and IDS are submitted herewith.

Please charge Deposit Account No. 10-0750/MCP264/MGM in the name of Johnson & Johnson for the cost of filing this Petition.

Respectfully submitted,

Bv

Michele S. Mangin (Attorney for Applicants)

Reg. No. 36,806

Dated: Q April 2003

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2810

Att.

mcp264.Withdrawlssue.doc